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The Epstein Barr virus (EBV) plays a role in maintenance of the tumor phenotype in a number of human cancers. The EBV latency replication
factor, EBNA1, is required for persistence of the EBVepisome, is anti-apoptotic, and is universally expressed in all EBV-associated tumors. Here,
we show that EBNA1-specific siRNAs can inhibit EBNA1 expression and function. siRNAs were generated against three target sites in the
EBNA1 messenger RNA, and two of these were found to inhibit EBNA1 expression from an ectopic EBNA1 expression cassette. EBNA1
siRNAs also inhibit endogenously expressed EBNA1 in EBV-positive epithelial and B-cell lines. Using a mini-EBV replication model, siRNA-
mediated inhibition of EBNA1 expression suppressed the episomal maintenance function of EBNA1. Lastly, introduction of an EBNA1 siRNA
into an EBV-positive tumor cell line inhibited tumor cell growth/survival. These data suggest that siRNAs against EBNA1 may have therapeutic
value in EBV-associated diseases.
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The Epstein Barr virus (EBV) is a ubiquitous human
herpesvirus that establishes a persistent infection and is carried
by greater than 90% of the world’s population. In immuno-
competent individuals, EBV contributes to a number of human
cancers including the endemic form of Burkitt’s lymphoma
(BL), nasopharyngeal carcinoma, Hodgkin’s disease, and a
small percentage of gastric carcinomas and T cell lymphomas
(Kieff, 1996; Miller, 1990; Young and Rowe, 1992). In
immuno-compromised individuals, EBV is more problematic,
and, despite the use of HAART therapies to treat AIDS
patients, there has been no significant change in the incidence
of many EBV-associated non-Hodgkin’s lymphomas (Buch-
binder et al., 1999; Calzolari et al., 1999; Dodd et al., 1992;
Green and Eversole, 1989; Jacobson et al., 1999; Ledergerber
et al., 1999).
EBV contributes to tumor maintenance and survival through
multiple mechanisms including cell cycle promotion, inhibition0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: eflemin@tulane.edu (E.K. Flemington).of apoptosis, and inhibition of inflammatory responses. Much
of the cell cycle promoting functions and the anti-apoptotic
functions of EBV are conferred through the expression of a
limited number of EBV genes that are expressed during the
latency phase of the life cycle. Nevertheless, low level
reactivation in a small percentage of cells is typically observed
in many tumors and may play a role in anti-inflammatory
responses since EBVencodes a potent IL10 which is expressed
during the lytic replicative cycle (Moore et al., 1990).
Furthermore, the immediate early gene product, Zta, was
shown to induce TGF-beta1 (Cayrol and Flemington, 1995).
Therefore, the contribution of EBV to the tumor phenotype is
complex, and any one of these pathways may be potential
targets for therapeutics.
From a therapeutic standpoint, an advantageous aspect of
virally associated tumors is that they harbor unique genetic
material that can theoretically be targeted without effecting
normal cell function. Targeting of viral genetic material may be
a viable means to specifically block key functions of viruses
without influencing regulatory pathways in normal uninfected
cells. Although the discovery that siRNA mechanisms are
conserved in mammalian systems is still relatively new, there is
a significant amount of interest in the possible application of6) 385 – 393
www.e
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part to the high level of efficacy observed for siRNA-mediated
gene inhibition and in part to the high level of specificity for
this approach. Although off-site targeting can occur and must
be considered and minimized in any application of siRNA-
based usage, the specificity is nevertheless very high relative to
many other therapeutic agents.
Although the pattern of latency-associated gene expression
varies considerably in different EBV-infected tissues, EBNA1
is unique in that it is universally expressed in all proliferating
EBV-infected cells. This strong association with proliferating
tissues, including tumor cells, is due partly to its requirement
for maintenance of the viral episomal genome during the cell
division cycle (Lee et al., 1999; Young et al., 2000). In addition
to its fundamental role in maintenance of the viral episome,
however, there is evidence that EBNA1 may also make a more
direct contribution to the tumor phenotype of EBV-associated
tumors. For example, Wilson et al. (1996) have shown that
EBNA1 induces B cell neoplasia in transgenic mice. A recent
report by Kennedy et al. (2003) showed that EBNA1 has anti-
apoptotic properties in most EBV-infected BL tumor lines in
tissue culture. For these reasons, EBNA1 may be a particularly
attractive target for therapeutic strategies. As mentioned above,
the contribution of EBV to the tumor phenotype is complex
and likely occurs through the effects of multiple EBV-encoded
genes (including lytic cycle associated genes). Targeting
EBNA1 function has the potential to impact all of these
mechanisms through loss of episomal maintenance as well as
impacting tumor survival more directly through the mitigation
of EBNA1’s tumorigenic/anti-apoptotic activities.Fig. 1. Analysis of EBNA1 siRNAs for inhibition of EBNA1 expression. (A) Struc
hundred millimeter plates containing Hela cells were transfected with 1 Ag of the EB
(cntl), pSUPER—E1(T1), pSUPER—E1(T2), or pSUPER—E1(T3) and analyzed f
using a monoclonal anti-EBNA1 antibody [Advance Biotechnologies (catalog no. 1Results
siRNA design
A series of potential EBNA1 siRNA target sites were
identified for the B95-8 strain of EBNA1 using a program
available online by OligoEngine (www.oligoengine.com). To
avoid possible non-specific effects, target sites within the Gly/
Ala repeat region of EBNA1 (Fig. 1A) were excluded since this
repeat region is highly homologous to human genomic repeat
sequences (Heller et al., 1985). Target sites outside of the
repeat regions were then blasted, and three target sites (referred
to as E1(T1), E1(T2), and E1(T3)) were identified which have
minimal homology to human genomic coding sequences.
Double-stranded oligonucleotides encoding hairpin structures
corresponding to these sites were cloned into the vector,
pSUPERretro (Brummelkamp et al., 2002).
Inhibition of ectopic EBNA1 expression
Cotransfection of 1 Ag of the pSUPERretro plasmids,
E1(T1), E1(T2), and E1(T3) with 1 Ag of an EBNA1
expression vector in 100 mm plates containing Hela cells
showed that E1(T1) moderately inhibits the expression of
EBNA1, while E1(T2) and E1(T3) more effectively inhibit the
expression of EBNA1 (Fig. 1B). In an effort to minimize any
non-specific effects of the siRNAs mediated through low
homology targeting of cellular targets or other activities
mediated by double-stranded RNA, titration experiments were
carried out to determine the lower end of input siRNA vectorsture of EBNA1 and position and sequence of siRNA target sites. (B–D) One
NA1 expression vector, pCEP4, plus the indicated amounts of either pSUPER
or EBNA1 expression by Western blot analysis 2 days following transfection
3-156-100)].
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transfection of as little as 12 ng of the E1(T3) targeting vector
(in a 100 mm plate (with 30 Ag of carrier DNA)) is sufficient to
inhibit EBNA1 expression. E1(T2) appears to be similarly
efficient for inhibition of EBNA1 expression, and, as shown in
Fig. 1D, 40 ng or 120 ng significantly inhibits EBNA1
expression.
Inhibition of EBNA1 replication function
Next, we used a vector, pCEP, which contains an EBNA1
expression cassette, the EBV origin of replication, and a hygro
selection marker as a mini-EBV replication model (Fig. 2A) to
assess whether EBNA1 siRNAs are sufficiently active to
inhibit EBNA1-mediated replication/episomal maintenance. As
shown in Fig. 2B, cotransfection of pCEP with 25 ng, 50 ng, or
100 ng of the control vector, pSUPERretro, had no influence
on the number of colonies arising after hygro selection. InFig. 2. Inhibition of episomal maintenance function of EBNA1 using mini-EBV rep
pBABE-hygro was cotransfected with the indicated amounts of either pSUPER (cnt
(for pCEP transfections) or 1:2 (pBABE-hygro transfection) in media containing 25contrast, cotransfection of 25 ng, 50 ng, or 100 ng of E1(T3)
with pCEP resulted in a marked reduction in the number of
colonies formed. Notably, a few colonies arise which may be
due to integration of the pCEP plasmid. To test whether the
reduction in colony formation in cells transfected with E1(T3)
is due to inhibition of cell growth mediated through possible
non-specific effects of the siRNA, cells were cotransfected with
the same concentrations of pSUPERretro (cntl) or E1(T3) and
the hygro containing plasmid, pBABE-hygro, which does not
contain EBNA1 or the EBV origin of replication. Hygro-
resistant colonies that arise from these transfections are due
specifically to integration of the pBABE-hygro vector and are
independent of EBNA1 replication function (note that since
integration is a rare event, approximately 5-fold more cells
were plated after these transfections than after the pCEP-hygro
transfections). As shown in Fig. 2B, similar numbers of
colonies are observed in E1(T3) transfections relative to the
control (pSUPERretro) transfected plates, indicating that thelication model. (A) Basis of selection assay. (B) 1 Ag of either pCEP (hygro) or
l) or pSUPER—E1(T3). Two days after transfection, cells were split either 1:10
0 Ag/ml hygromycin. Cells were stained 10–14 days later to visualize colonies.
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tions is likely to be specifically due to inhibition of EBNA1
function and not non-specific inhibition of cell growth.
As additional specificity controls, we generated pCEP
plasmids that contain conservative mutations in either the T2
or the T3 target sites of EBNA1 (Fig. 3A). While these
mutations do not alter the amino acid sequence in the target
region, they are sufficient to prevent significant inhibition by
their respective siRNA (Fig. 3B) [It should be noted that these
mutants were generated using a PCR mutagenesis approach
and sequence analysis of the EBNA1 or for each mutant
revealed deletions in the Gly/Ala repeat region. These deletions
do not affect EBNA1’s replication/episomal maintenance
function (data not shown and see below), but they do result
in alterations in its mobility on Western blots (right panel of
Fig. 3B)]. The pCEP (T2) mutant was used to further assess the
specificity of the E1(T2) siRNA plasmid in inhibiting EBNA1-
mediated replication/plasmid maintenance. As shown in Fig.
3C, while E1(T2) significantly inhibited colony formation of
pCEP, it had no impact on colony formation in pCEP(T2mut)
transfected cells, further establishing that inhibition of colonyFig. 3. Conservative mutations in the siRNA target sites of EBNA1 inhibit targetin
dependent episomal maintenance function. (A) Illustration of conservative mutations
indicated plasmids and assayed for EBNA1, EBNA1 (T2mut), or EBNA1 (T3mut) e
EBNA1 antibody [Advance Biotechnologies (catalog no. 13-156-100)]). [Note: in 2
transfected with 1 Ag of either pCEP or a pCEP plasmid containing the T2 mutatio
scrambled T2 sequence and serves as an additional negative control.formation in pCEP transfected cells is due to specific inhibition
of EBNA1 function and not non-specific effects of the siRNA
itself.
Influence of strain variation on siRNA targeting
Since possible strain variation at target sites can influence
the ability of siRNAs to target endogenous EBNA1 expression,
we amplified a region spanning the T2 and T3 target sites from
selected cell lines carried in our laboratory and determined the
sequence. The high fidelity polymerase, Pfu, was used, and
two separate PCR reactions was carried out for each cell line.
In every case, the sequence for both PCR reactions was
identical, indicating that the sequence was accurate and not due
to PCR errors. In addition, PCR was carried out on a cell line
(Boston) that was generated in our laboratory using B95-
8 virus, and these sequences matched the published B95-
8 sequence. As shown in Fig. 4A, sequence differences were
observed in MutuI and Rael cells at both the T2 and the T3
target sites. A previous study has reported changes in the
amino acid sequence of EBNA1 from 13 different cell linesg by E1(T2) and E1(T3) siRNAs and prevent functional inhibition of EBNA1-
in siRNA target sites of EBNA1. (B) Hela or 293 cells were transfected with the
xpression 2 days after transfection by Western blot analysis (using a monoclonal
93 cells, only the upper EBNA1 form is shown for clarity] (C) Hela cells were
n plus 250 ng of the indicated pSUPER-based plasmids. E1(T2cntl) contains a
Fig. 4. Analysis of siRNA efficacy with target site strain variants and inhibition of endogenous EBNA1 expression. (A) The T2 and T3 target sites of EBNA1 of
MutuI, Rael, and Boston cells were cloned and sequenced. The sequences for Akata and NPC-KT were derived from Chen et al. (note: since only the amino acid
sequence was reported in this paper, we cannot discern whether some lines have more than 3 mutations). (B) Hela cells were transfected with 1 Ag of pCEP plus 100
ng of the indicated pSUPERretro-based plasmids and assayed for EBNA1 expression by Western blot analysis (Ab). (C) DG75 cells were electroporated with 2 Ag of
the indicated EBNA1 expression vectors plus 500 ng of the indicated pSUPERretro plasmids by electroporation and assayed for EBNA1 expression 2 days later. For
ease of interpretation, only the upper more prominent form of EBNA1 is shown. (D) B95-8 cells were infected with the indicated pSUPERretro siRNA viruses, and
puromycin was added 1 day later. Cells were then assayed for EBNA1 expression 1, 2, 3, and 4 days later. Western blot analysis in panels B–F were carried out
using a monoclonal antibody against EBNA1 [Advance Biotechnologies (catalog no. 13-156-100)].
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reported to have the B95-8 sequence at the T2 site, while 4
were shown to have the C–A mutation observed in MutuI
cells. Considerably more variation was observed at the T3 site
with most lines showing at least 2 or 3 differences from the
B95-8 sequence.
Three additional derivatives of the T2 and T3 siRNAs were
generated in pSUPERretro, one for the T2 site which contains
the C–A mutation observed in MutuI cells, one T3 variant
which contains the C–T mutation seen in MutuI cells, and
another which contains a C–A variant of the same position in
T3. To test whether these alterations influence the ability of the
T2 or T3 siRNAs to target the B95-8 strain of EBNA1, the T2,
T3, or the variants were cotransfected with the B95-8-derived
EBNA1 expression vector in Hela cells, and EBNA1 expres-
sion was assessed by Western blot analysis (Fig. 4B). While the
E1(T2 C–A) variant was able to suppress B95-8 EBNA1
expression, neither of the T3 variants suppressed B95-
8 EBNA1 expression. This indicates that, in some cases, a
one nucleotide mismatch in an siRNA sequence can still
mediate inhibition, while, in others, a one nucleotide mismatch
is not tolerated. The E1(T2 C–A) mutant similarly targeted the
B95-8 strain of EBNA1 in DG75 cells. Since the T2 site is
more conserved and since there is some cross strain targeting atthe T2 site, this may represent a more useful siRNA for
possible therapeutic applications.
Inhibition of endogenous EBNA1 expression
To test whether endogenous EBNA1 expression can be
inhibited by the T2 siRNA, pSUPERretro, pSUPERretro-
E1(T1), pSUPERretro-E1(T2), or a vector containing a
scrambled T2 sequence (E1(T2cntl)) was packaged and
introduced into B95-8 cells through retroviral transduction.
Retroviral transduction was used since introduction of exog-
enous DNAs into these cells is significantly higher using this
method compared to transfection methods. After day one, puro
was added to select for successfully infected cells. As shown in
Fig. 4D, while E1(T1) and E1(T2cntl) failed to inhibit EBNA1
expression, E1(T2) inhibited EBNA1 expression starting at day
2 and more significantly by day 4. This indicates that
endogenous EBNA1 can be specifically inhibited by the E1
(T2) siRNA.
Inhibition of EBV-associated tumor cell growth
The next issue that we wanted to assess was whether
E1(T2) can inhibit the survival of EBV-positive tumor cells.
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generated through the fusion of a primary nasopharyngeal
carcinoma and hypoxanthine-guanine phosphoribosyltransfer-
ase (HGPRT)-defective cells derived from adenoid tissues. In
NPC-KT cells, long-term persistence of EBV is observed in
tissue culture, suggesting that EBV may be required for
survival or growth of these cells. Nevertheless, since it is
possible that EBV is integrated in these cells and persists
simply due to co-segregation with the corresponding chromo-
some(s), we first tested whether these cells require the
function of EBNA1. A dominant negative form of EBNA1
(EBNA1dn) was generated and tested for its ability to inhibit
outgrowth of colonies in NPC-KT cells. Either a control
plasmid or a plasmid expressing EBNA1dn was transfected
into NPC-KT cells and was subjected to selection with
puromycin. As shown in Fig. 5A, EBNA1dn inhibited colony
formation indicating a survival function for EBNA1 in these
cells.Fig. 5. Inhibition of NPC-KT colony formation by E1(T2) siRNA. (A) NPC-KT cel
and cultured in 1 mg/ml G418 containing media for 12 days. (B) Hela cells were tran
amounts of T2 duplex siRNAs (upper panel). B95-8 and NPC-KT cells were transfec
(ordered from Dharmacon) (middle panel). Endogenous EBNA1 in NPC-KT cells w
NPC-KT cells were transfected with 50 nM T2 duplex RNA or 50 nM siGLO in fou
colony formation. (C) NPC-KT cells and a stable NPC-KT EBNA1 (T2mut) clon
transfections were carried out at a 2-day interval, and cells were plated to assess
EBNA1(T2mut) clone was transfected in three successive transfections with 100 nM
formation.To assess the ability of an EBNA1 siRNA to inhibit the
growth or NPC-KT cells, we used a non-vector-based siRNA
[i.e. RNA/RNA hybrids (duplex RNA)] to avoid any possible
side effects reported previously for hairpin structures (1).
Double-stranded RNAs against the T2 site of EBNA1 were
first tested for inhibition of ectopic EBNA1 in Hela cells. As
shown in Fig. 5B, duplex RNA inhibited EBNA1 expression at
concentrations as low as 1 nM. In addition, T2 duplex RNA
inhibited endogenous EBNA1 expression in B95-8 and NPC-
KT cells (Fig 5B).
To test whether T2 duplex RNA can inhibit growth of NPC-
KT cells, T2 duplex RNA or a control siRNA (siGLO) was
transfected using lipofectamine 2000, and cells were plated to
assess colony formation. As shown in the lower panel of Fig.
5B, fewer colonies were observed in cultures transfected with
the T2 duplex RNA vs. control. To determine whether
inhibition is specifically due to the EBNA1 inhibitory function
or non-specific effects of the siRNA, NPC-KT clones expres-ls were transfected with 1 Ag of either pMSCV-neo (cntl) or pMSCVneo-E1dn
sfected with EBNA1 and EBNA1 (T2mut) expression vectors plus the indicated
ted with the indicated amounts of either duplex T2 RNA or siSTABLE T2 RNA
as detected using a human serum reactive to NPC-KT EBNA1. Lower panel:
r successive transfections (at a 2-day intervals). Cells were then plated to assess
e were transfected with T2 duplex RNA or the control siRNA, siGLO. Four
colony formation. (D) NPC-KT control clones, Cl1 and Cl2, or the NPC-KT
duplex T2 RNA or the control siRNA, siGLO. Cells were then plated for colony
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while T2 duplex RNA inhibits colony formation of the parental
NPC-KT cells, there is little inhibition of an NPC-KT clone
expressing the EBNA1(T2mut). Furthermore, T2 siRNA
inhibits colony formation of two NPC-KT clones containing
the EBNA1(T2mut) control plasmid but not NPC-KT
EBNA1(T2mut) cells (Fig. 5D). Therefore, the observed
inhibition of NPC-KT cell growth is due to inhibition of
EBNA1 function and not secondary effects of the siRNA.
Discussion
Previous studies have shown that siRNAs directed against
RNA viruses including human immunodeficiency virus (HIV),
hepatitis C virus (HCV), and influenza virus may have
potential therapeutic value in inhibiting virus propagation (Ge
et al., 2003; Jacque et al., 2002; Kapadia et al., 2003; Novina et
al., 2002; Randall et al., 2003). The use of siRNA technology
to inhibit pathologies associated with DNA viruses requires
specific targeting of the mRNA of genes that are required for
key viral functions. Several reports have shown that targeting
the human papilloma virus (HPV)-encoded oncogenes, E6 and
E7, may be a viable means of inhibiting the survival of HPV-
associated malignancies (Butz et al., 2003; Hall and Alexander,
2003; Jiang and Milner, 2005). In our study, we have
developed siRNAs against the EBV-latency-associated gene,
EBNA1, which is ubiquitously expressed in all proliferating
EBV-associated tissues. Since EBNA1 is required for mainte-
nance of the viral episome, inhibition of EBNA1 function may
ultimately lead to the loss of viral genomes with the
concomitant loss of cell cycle promoting functions, anti-
apoptotic functions, and anti-inflammatory functions of other
EBV-encoded gene products. In addition, EBNA1 itself has
been shown to promote tumorigenesis and to provide an anti-
apoptotic response in B cell tumors. Therefore, EBNA1 may be
an effective target in therapeutic strategies against EBV-
associated malignancies.
A recent report has shown that adenoviral delivery of a
dominant negative form of EBNA1 into EBV-associated tumor
cells effectively inhibits tumor growth (Nasimuzzaman et al.,
2005), supporting the contention that blocking EBNA1
function may ultimately be a viable strategy for treating
EBV-associated tumors. The use of EBNA1 siRNAs may have
some advantages over dominant negative forms of EBNA1 in
that they cannot only be delivered through viral transduction
but can also be delivered directly using duplex RNAs. The use
of duplex siRNAs avoids some of the immunological reactivity
problems associated with adenoviral vectors, and the continued
development of modifications to siRNAs which enhance
stability and efficacy may ultimately make siRNAs a preferred
method for inhibiting EBNA1 function.
We have identified two siRNAs target sites in the EBNA1
RNA that are effective in inhibiting EBNA1 expression and
replication function, and we have shown that one of these sites
(T2) can inhibit tumor cell growth in an EBV-positive tumor cell
line. While the functional inhibition experiments were carried
out using cells containing virus with the B95-8 T2 sequence, it isalso likely that strains carrying the other major T2 genotype (the
C–Avariant) may similarly be effectively targeted using siRNA
containing this variant sequence. In addition, changes at this
position can be tolerated without abolishing the ability of an
siRNA to target EBNA1 expression so even single siRNAs may
be able to target multiple viral strains. At the T3 site, there
appears to be a higher level of restriction for strain differences
observed at position 11. Changing the cytosine at position 11 to
either a Tor an A abolished the ability of the B95-8 T3 siRNA to
target EBNA1. Therefore, targeting EBNA1 through the T3 site
will require the use of siRNAs with the appropriate siRNA
variant sequence.
In conclusion, we have shown that EBNA1-specific siRNAs
can inhibit EBNA1 function and that they can inhibit the
growth/survival of an EBV-associated cell line that requires
EBNA1 function in tissue culture. These data support the idea
that EBNA1-specific siRNAs may have potential therapeutic
value in treating EBV-associated tumors, and we believe that
this line of investigation warrants further investigation.
Materials and methods
Cell culture
Hela, 293, and NPC-KT cell lines were cultured in
Dulbecco’s Modified Eagles Medium (DMEM) containing
10% fetal bovine serum (FBS). DG75, MutuI, Rael, and B95-
8 cells were cultured in RPMI plus 10% fetal bovine serum.
Drug selections were carried out using either 250 Ag/ml
hygromycin, 1 Ag/ml puromycin, or 1 mg/ml G418.
Electroporation
Cultures were grown to near saturation in RPMI (+10%
FBS, +Pen/Strep). The day before electroporation, an equal
volume of fresh media [RPMI (+10% FBS, +Pen/Strep)] was
added. Cells were counted, spun down, and 3  107 cells were
suspended in 0.4 ml RPMI for each sample. A total of 30 Ag of
DNA was added including the indicated amounts of plasmid
plus carrier DNA (the plasmid, pGL3basic). Electroporations
were carried out using a BTX Electrocell Manipulator,
ECM600 using the following conditions: voltage = 265,
capacitance = 975 AF, resistance = 720 V. After discharge,
0.6 ml of RPMI was added, and cell suspension was
immediately pipetted up and down several times and trans-
ferred to a T25 flask containing 10 ml RPMI (+10% FBS,
+Pen/Strep). Cells were cultured for 48 h prior to harvesting.
Calcium phosphate transfection
A modified calcium phosphate precipitation method was
used for transfections. Briefly, cells were plated the day before
transfection onto 100 mm tissue culture plates. The next
morning, the media was replaced with 8 ml of DME containing
10% FBS. 6–8 h later, DNA precipitates were formed using
the indicated plasmids plus the carrier plasmid, pGL3basic (for
a total amount of 30 Ag DNA). DNAs were added to 500 Al 1
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50 mM KCl, 0.7 mM Na2HPO4, pH 7.1). Thirty microliters of
2.5 M CaCl2 was then added, and the samples were mixed
immediately. After 20 min at room temperature, precipitates
were added dropwise to tissue culture plates. 16–20 h later, the
media was replaced with fresh DME (+10% FBS, +Pen/Strep)
1 HBS.
Duplex RNA transfections
siRNAs were introduced into cells using lipofectamine 2000
(InVitrogen, Cat. #11668-019). Transfections were carried out
essentially as described in the manufacturer’s instructions with
minor modifications. Briefly, 1 day before transfection, 2  105
cells were plated into each well of a 6-well plate in 2 ml DME
(+10% FBS, +Pen/Strep). Immediately before transfection, the
media was replaced with 1.5 ml of fresh DME (without FBS or
Pen/Strep). Five microliters lipofectamine 2000 was diluted in
250 Al DME (without FBS or Pen/Strep) for each transfection
and mixed with the indicated amounts of siRNAs (diluted in 250
Al serum and antibiotic-free DME). Mixtures were incubated for
20 min at room temperature prior to the dropwise addition to
cells. The cells were kept in transfection medium for 8 h before
media was replace with fresh DME (+10% FBS, +Pen/Strep).
Forty eight hours later, the cells were split for either subsequent
transfection, Western blot analysis, or cell colony assays.
Retroviral infection
293 cells were cotransfected with 10 Ag of retroviral plasmid,
10 Ag each of the packaging plasmids, VPACK-GPdI and pCI-
VSV-G (generous gift of Dr. Brian Schaefer) using calcium
phosphate transfection. The next morning, the media was
replaced with 10 ml of fresh DME (+10% FBS). Twenty four
hours later, viral supernatants were taken, spun 2 at 500 g to
precipitate floating 293 cells, and used for infections. B95-8 cells
were spun down and suspended in DME (+10%FBS) containing
16 Ag/ml polybrene, and 1 ml was added to each well of a 6-well
plate. One milliliter of viral supernatant was then added to each
well of 6-well plate and mixed. Plates were incubated for 1 h in
37 -C incubator, spun for 1 h at 1000  g, and then incubated
again in a 37 -C incubator for 3 h. Cells from 6 wells were then
collected, spun down, suspended in 12 ml RPMI (+10% FBS),
and placed in 37 -C 5% CO2 incubator.
Western blot analysis
Cells were spun down, washed one time with 1 PBS, and
suspended in 15 pellet volumes of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading
(Laemmli) buffer (Maniatis et al., 1982). Samples were then
boiled for 20 min to shear DNA, and lysates were subjected to
SDS-PAGE separation and transferred to nitrocellulose mem-
branes. The blots were blocked for 30min in Tris-buffered saline
containing 5% low-fat powdered mild and 1% fetal bovine
serum and then incubated with the indicated primary antibody
(in blocking buffer) for either 1 h at room temperature orovernight at 4 -C. The blots were washed once with 1 PBS,
once with 1 PBS buffer containing 0.5% (vol/vol) Tween 20,
and twice with 1 PBS buffer alone (each was carried out for
approximately 15 min). The blots were then incubated with
peroxidase-conjugated secondary antibody in blocking buffer
for 1 to 2 h at room temperature. Blots were washed as described
above and analyzed with an enhanced chemiluminescence
detection system (Amersham) according to manufacturer’s
recommendations, and filters were exposed to Kodak XR film.
Antibodies used are indicated in respective figure legends.
PCR and sequencing
The ultra high fidelity PCR system from Stratagene (Cat
#600166) was used to amplify the EBNA1 T2/T3 region from
MutuI, Rael, and Boston cells using the primers, left primer: 5V-
AAGGAGGGTGGTTTGGAAAG-3V, and right primer (Bos-
ton, B95-8): 5V-TGGAATAGCAAGGGCAGTTC-3V, right
primer (Mutu, Rael): 5V-TGGAATAGCAAGGCCAATTCC-3V.
PCR reactions were carried out using the following conditions:
denaturation—95 -C (30 s), annealing—62 -C (30 s), and
extension—72 -C (30 s), 20 cycles. PCR products were purified
using the QIAquick gel extraction kit (Qiagen) and sequenced.
Cloning
The E1(T1), E1(T2), and E1(T3) siRNA vectors were
generated by cloning synthetic double-stranded 64-mer oligo-
nucleotides (designed based on program on the web site,
www.oligoengine.com) containing HindIII and BglII over-
hangs into pSUPER and pSUPERretro. Cloning into HindIII
and BglII digested pSUPERretro proved difficult since the
HindIII and BglII sites are adjacent to each, making digestion
with both enzymes a rare event. Oligos were therefore cloned
into BglII and XhoI cut pSUPER and pSUPERretro with the
addition of a HindIII/XhoI adaptor from eZclone Systems, LLC
(New Orleans). All other siRNAs were designed with BglII and
XhoI overhangs and cloned directly into BglII and XhoI cut
vectors. All clones were sequenced, and clones with no errors
were used for analysis. Site-directed mutagenesis of EBNA1
was carried out using the Stratagene QuickChange site-directed
mutagenesis kit according to manufacturer’s recommendations.
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